ACUR: AI 评分 48/100 — AI 分析 (4月 2026)

Acura Pharmaceuticals, Inc. focuses on developing and commercializing technologies to improve medication safety. The company's portfolio includes products targeting pain management and nasal congestion, with ongoing efforts to expand its product pipeline.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Acura Pharmaceuticals, Inc. is a drug delivery company focused on developing and commercializing technologies for safer medication use, particularly in pain management and nasal decongestion. Its product portfolio includes Oxaydo and Nexafed, with ongoing research into abuse-deterrent formulations and collaborative agreements for global market expansion.

ACUR是做什么的？

Acura Pharmaceuticals, Inc., established in 1935 and headquartered in Palatine, Illinois, is dedicated to the research, development, and commercialization of pharmaceutical products designed to improve medication safety. The company's primary focus is on creating innovative drug delivery technologies that address the challenges associated with prescription drug abuse and misuse. Acura's product portfolio includes Oxaydo, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Additionally, the company offers Nexafed products, which are pseudoephedrine and acetaminophen tablets used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy medications. Acura Pharmaceuticals operates through strategic collaboration and license agreements with companies like Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC. These partnerships enable Acura to manufacture, commercialize, and further develop its product offerings, including LTX-03, an immediate-release tablet utilizing LIMITx technology. With a lean team of 9 employees, Acura Pharmaceuticals continues to innovate in the drug delivery space, aiming to provide safer and more effective medication options.

ACUR的投资论点是什么？

Acura Pharmaceuticals, Inc. presents a focused investment opportunity within the specialty pharmaceutical sector. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management. Key value drivers include the potential for increased adoption of Oxaydo and Nexafed products, coupled with successful development and commercialization of its pipeline products, including LTX-03. The company's gross margin of 94.2% indicates strong pricing power. However, the company's negative profit margin of -56.2% and negative free cash flow of $-0.00B highlight the need for improved financial performance. Upcoming catalysts include potential regulatory approvals for new formulations and expansion of existing product lines. Potential risks include competition from established pharmaceutical companies and challenges in securing additional funding for research and development.

ACUR在哪个行业运营？

Acura Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on developing niche products and innovative drug delivery systems. The industry is driven by the need for safer and more effective medications, particularly in areas such as pain management and abuse deterrence. The competitive landscape includes both large pharmaceutical companies and smaller, specialized firms. Acura's focus on abuse-deterrent formulations positions it within a growing segment of the market, driven by increasing concerns about opioid abuse and regulatory pressures to develop safer alternatives. The global pharmaceutical market is projected to reach trillions of dollars by 2026, with specialty pharmaceuticals representing a significant portion of this growth.

Drug Manufacturers - Specialty & Generic

Healthcare

ACUR有哪些增长机遇？

Expansion of Oxaydo Market Share: Acura has the opportunity to increase the market share of Oxaydo, its abuse-deterrent opioid, by targeting specific patient populations and expanding its distribution network. The market for abuse-deterrent opioids is growing due to increasing awareness of opioid abuse and regulatory initiatives promoting safer pain management options. Success in this area could significantly boost revenue within the next 2-3 years.
Commercialization of LTX-03: The successful development and commercialization of LTX-03, an immediate-release tablet utilizing LIMITx technology, represents a significant growth opportunity for Acura. This product aims to provide effective pain relief while minimizing the risk of abuse. Positive clinical trial results and regulatory approval could lead to substantial revenue generation within the next 3-5 years.
Geographic Expansion: Acura can explore opportunities to expand its geographic reach by partnering with international distributors or establishing a direct presence in key markets. The global market for pain management and nasal decongestant products is substantial, and expanding into new regions could drive significant revenue growth over the next 5 years.
Development of New Abuse-Deterrent Formulations: Acura's expertise in drug delivery technology positions it to develop new abuse-deterrent formulations for other commonly abused medications. This could involve partnering with other pharmaceutical companies or developing its own proprietary products. Successful development and commercialization of new formulations could create new revenue streams within the next 3-5 years.
Strategic Partnerships and Acquisitions: Acura can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. This could involve acquiring companies with complementary technologies or products, or partnering with larger pharmaceutical companies to co-develop and commercialize new medications. Such partnerships could accelerate growth and diversify revenue streams over the next 2-5 years.

Gross Margin of 94.2% indicates strong pricing power in its product offerings.
Negative Profit Margin of -56.2% reflects ongoing investments in research and development and commercialization efforts.
Free Cash Flow of $-0.00B indicates the company is currently reliant on external funding.
Beta of -54.49 suggests the stock price is inversely correlated with the market.
The company has six additional opioid products in various stages of formulation development, signaling future growth potential.

ACUR提供哪些产品和服务？

Develops and commercializes pharmaceutical products.
Focuses on abuse-deterrent drug delivery technologies.
Offers Oxaydo tablets for pain management.
Provides Nexafed products for nasal decongestion.
Engages in research and development of new formulations.
Collaborates with other pharmaceutical companies for product development and commercialization.

ACUR如何赚钱？

Develops and patents proprietary drug delivery technologies.
Manufactures and sells pharmaceutical products through partnerships and direct sales.
Generates revenue through product sales and licensing agreements.
Invests in research and development to expand its product pipeline.

Patients suffering from acute and chronic pain.
Individuals seeking relief from nasal congestion.
Pharmaceutical companies seeking to incorporate abuse-deterrent technologies into their products.
Distributors and wholesalers of pharmaceutical products.

Proprietary drug delivery technologies that enhance medication safety.
Patents protecting its formulations and technologies.
Established partnerships with other pharmaceutical companies.
Expertise in developing abuse-deterrent formulations.

什么因素可能推动ACUR股价上涨？

Upcoming: Potential regulatory approval for new abuse-deterrent formulations.
Upcoming: Expansion of existing product lines into new markets.
Ongoing: Research and development of new drug delivery technologies.
Ongoing: Strategic partnerships with other pharmaceutical companies.
Ongoing: Efforts to increase market share for Oxaydo and Nexafed.

ACUR的主要风险是什么？

Potential: Competition from larger pharmaceutical companies with greater resources.
Potential: Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations.
Potential: Challenges in securing funding for research and development.
Ongoing: Dependence on key partnerships for product development and commercialization.
Ongoing: Limited liquidity due to trading on the OTC market.

ACUR的核心优势是什么？

Proprietary abuse-deterrent drug delivery technologies.
Established partnerships with other pharmaceutical companies.
Focus on a growing market segment (abuse-deterrent formulations).
High gross margin (94.2%).

ACUR的劣势是什么？

Negative profit margin (-56.2%).
Negative free cash flow.
Small number of employees (9).
Limited product portfolio.

ACUR有哪些机遇？

Expansion of Oxaydo market share.
Commercialization of LTX-03.
Geographic expansion.
Development of new abuse-deterrent formulations.

ACUR面临哪些威胁？

Competition from larger pharmaceutical companies.
Regulatory changes impacting opioid prescriptions.
Challenges in securing funding for research and development.
Potential product liability claims.

ACUR的竞争对手是谁？

AzureFilm — Focuses on 3D printing filaments. — (AZFL)
CBD of Denver, Inc. — Operates in the cannabis industry. — (CBDX)
Cannabics Pharmaceuticals Inc. — Develops cannabis-based pharmaceuticals. — (CNBX)
Flora Growth Corp. — Focuses on cannabis cultivation and distribution. — (FLHLF)
Grov Technologies, Inc. — Develops automated vertical farming systems. — (GMVDF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Robert Jones
Headquarters: Palatine, US
Employees: 9
Founded: 1986

AI Insight

AI analysis pending for ACUR

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Acura Pharmaceuticals, Inc. do?

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products with abuse-deterrent properties. Their portfolio includes Oxaydo, an immediate-release oxycodone tablet formulated to deter abuse, and Nexafed, a pseudoephedrine tablet designed to resist methamphetamine production. The company leverages its proprietary Aversion and Impede technologies to create safer versions of commonly abused medications, addressing the critical need for abuse-deterrent options in pain management and other therapeutic areas. Acura operates through strategic partnerships and internal research and development efforts.

What do analysts say about ACUR stock?

AI analysis is currently pending for ACUR. Without analyst ratings or price targets, it is difficult to assess market sentiment or potential valuation. Investors should conduct their own due diligence and consider the company's financial performance, product pipeline, and competitive landscape before making any investment decisions. Key metrics to monitor include revenue growth, profitability, and progress in developing and commercializing new abuse-deterrent formulations.

What are the main risks for ACUR?

Acura Pharmaceuticals, Inc. faces several risks inherent to the pharmaceutical industry and its specific business model. Competition from larger pharmaceutical companies with greater resources poses a significant threat. Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations could also negatively affect the company's prospects. Securing funding for research and development is crucial for Acura's long-term success, and any challenges in this area could hinder its growth. Furthermore, the company's reliance on key partnerships exposes it to risks associated with the performance and strategic decisions of its collaborators.

What revenue streams does Acura Pharmaceuticals, Inc. have in healthcare?

Acura Pharmaceuticals, Inc. generates revenue primarily through the sale of its pharmaceutical products, Oxaydo and Nexafed. Oxaydo, an abuse-deterrent opioid, contributes to revenue through prescriptions for pain management. Nexafed, a nasal decongestant, generates revenue through over-the-counter and prescription sales. Additionally, Acura may receive revenue from licensing agreements and partnerships related to its proprietary drug delivery technologies. The company's revenue streams are concentrated in the United States, with potential for future expansion into international markets through strategic partnerships.

How does Acura Pharmaceuticals, Inc. address the opioid crisis?

Acura Pharmaceuticals, Inc. addresses the opioid crisis by developing and commercializing abuse-deterrent formulations of opioid medications. Its Oxaydo tablets are designed to be more difficult to crush, snort, or inject, reducing the potential for misuse and abuse. By providing safer alternatives to traditional opioid painkillers, Acura aims to contribute to the reduction of opioid-related addiction and overdose. The company's focus on abuse-deterrent technology aligns with regulatory efforts to combat the opioid crisis and promote responsible pain management practices.